CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 80 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,719,151 | +117.1% | 461,303 | +31.5% | 0.00% | +100.0% |
| Q2 2023 | $6,320,299 | +13.9% | 350,738 | +1.5% | 0.00% | 0.0% |
| Q1 2023 | $5,549,806 | -11.6% | 345,567 | +0.7% | 0.00% | 0.0% |
| Q4 2022 | $6,277,907 | -4.9% | 343,055 | +2.0% | 0.00% | 0.0% |
| Q3 2022 | $6,603,000 | +6.7% | 336,190 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $6,186,000 | -5.5% | 331,671 | +11.3% | 0.00% | 0.0% |
| Q1 2022 | $6,544,000 | -20.5% | 298,125 | +2.9% | 0.00% | 0.0% |
| Q4 2021 | $8,232,000 | +75.1% | 289,735 | +29.8% | 0.00% | 0.0% |
| Q3 2021 | $4,700,000 | +27.2% | 223,247 | +13.9% | 0.00% | +100.0% |
| Q2 2021 | $3,694,000 | +60.3% | 195,921 | +30.0% | 0.00% | 0.0% |
| Q1 2021 | $2,304,000 | +8.3% | 150,752 | +0.0% | 0.00% | 0.0% |
| Q4 2020 | $2,127,000 | -7.6% | 150,723 | +2.6% | 0.00% | 0.0% |
| Q3 2020 | $2,302,000 | -2.7% | 146,871 | +8.8% | 0.00% | 0.0% |
| Q2 2020 | $2,365,000 | +204.8% | 134,974 | +156.0% | 0.00% | – |
| Q1 2020 | $776,000 | -41.6% | 52,722 | -0.4% | 0.00% | -100.0% |
| Q4 2019 | $1,329,000 | +73.0% | 52,947 | +3.8% | 0.00% | – |
| Q3 2019 | $768,000 | -33.4% | 51,003 | +10.5% | 0.00% | -100.0% |
| Q2 2019 | $1,154,000 | +26.0% | 46,146 | +14.7% | 0.00% | 0.0% |
| Q1 2019 | $916,000 | -9.8% | 40,217 | +18.7% | 0.00% | 0.0% |
| Q4 2018 | $1,016,000 | -1.7% | 33,874 | -6.1% | 0.00% | 0.0% |
| Q3 2018 | $1,034,000 | – | 36,066 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |